Company intelligence / Profile preview

Pharmacyclics

Sunnyvale, California, United Statespharmacyclics.com ↗

Ownership: Public · ABBV
Employees: ~500
Development stage: Commercial

Overview

Pharmacyclics developed Imbruvica® (ibrutinib), a first-in-class oral BTK inhibitor that became a blockbuster therapy for several hematological cancers. The company achieved rapid revenue growth following FDA approvals and was acquired by AbbVie in one of the largest biotech deals in history. At the time of acquisition, Imbruvica had multiple approved indications and an extensive clinical development program exploring further uses[3][6].

Therapeutic areas: Oncology
Modalities: small molecules
Industry: Biotech

Drug pipeline

9 assets

ibrutinib

Approved

8 more assets in the full pipeline.

Request access →

Partnerships

Janssen Biotech/Johnson & Johnson

Beyond the preview

Go deeper on Pharmacyclics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmacyclics.

Explore the full profile